Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.
Stocks · News reference
Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.
8-K filing — Structure Therapeutics Inc. (GPCR)
Filed: 2026-09-08 AccNo: 0001104659-26-105688 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits